Septerna (SEPN) Common Equity (2023 - 2026)
Septerna (SEPN) posted quarterly Common Equity of $378.5 million for Q1 2026, up 194.55% year-over-year from $128.5 million in Q1 2025, and down 0.91% quarter-over-quarter from $381.9 million in Q4 2025.
Septerna (SEPN) Common Equity (2023 - 2026) Analysis & Trends
Septerna's Common Equity history runs 4 years deep, the most recent figure standing at $378.5 million for Q1 2026.
- In Q1 2026, Common Equity rose 194.55% year-over-year to $378.5 million; the TTM figure through Mar 2026 stood at $378.5 million (up 194.55% YoY), while the FY2025 annual figure was $381.9 million, down 9.08% from the prior year.
- Common Equity for Q1 2026 stood at $378.5 million, down from $381.9 million in the prior quarter.
- The five-year high for Common Equity was $420.0 million in Q4 2024, with the low at -$400.3 million in Q1 2025.
- The 4-year median for Common Equity is -$38.4 million (2023), against an average of $111.6 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity surged 1194.61% in 2024, then sank 671.31% in 2025.
- Septerna's Common Equity stood at -$38.4 million in 2023, then soared by 1194.61% to $420.0 million in 2024, then dropped by 9.08% to $381.9 million in 2025, then fell by 0.91% to $378.5 million in 2026.
- Business Quant data shows SEPN's Common Equity at $378.5 million in Q1 2026, $381.9 million in Q4 2025, and $388.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Septerna | 2.08 Bn | 2.08 Bn | - | 386.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 386.72 Mn |
| Mar 31, 2026 | 378.46 Mn |
| Dec 31, 2025 | 381.93 Mn |
| Sep 30, 2025 | 388.73 Mn |
| Jun 30, 2025 | 377.56 Mn |
| Mar 31, 2025 | -400.27 Mn |
| Dec 31, 2024 | 420.05 Mn |
| Sep 30, 2024 | -87.41 Mn |
| Jun 30, 2024 | -67.76 Mn |
| Mar 31, 2024 | -51.89 Mn |
| Dec 31, 2023 | -38.37 Mn |
| Sep 30, 2023 | -73.85 Mn |